Published in

Elsevier, The Lancet Infectious Diseases, 5(16), p. 576-583, 2016

DOI: 10.1016/s1473-3099(15)00547-2

Links

Tools

Export citation

Search in Google Scholar

Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study

Journal article published in 2016 by Kerryn A. Moore, Julie A. Simpson, Moo Kho Paw ORCID, MuPawJay Pimanpanarak, Jacher Wiladphaingern, Marcus J. Rijken ORCID, Podjanee Jittamala, Nicholas J. White, Freya J. I. Fowkes, François Nosten, Rose McGready
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Artemisinins, the most effective antimalarials available, are not recommended for falciparum malaria during the first trimester of pregnancy because of safety concerns. Therefore, quinine is used despite its poor effectiveness. Assessing artemisinin safety requires weighing the risks of malaria and its treatment. We aimed to assess the effect of first-trimester malaria and artemisinin treatment on miscarriage and major congenital malformations.